JW Therapeutics (Shanghai) Co., Ltd.

Payment triggered by development milestone achieved by Regeneron’s collaborator in China, JW TherapeuticsProgresses first clinical use of Medigene’s End-to-End Platform to generate potentially best-in-class TCRs Planegg/Martinsried, December 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced a USD $1 million milestone payment from Regeneron Pharmaceuticals, Inc. was triggered. Regeneron purchased the MAGE-A4-TCR program as part of its acquisition of 2seventy bio Inc.’s pre-clinical and clinical oncology and autoimmune cell therapy pipeline, which closed in April 2024. The payment was triggered by a development milestone for a trial in China led by JW Therapeutics (also a prior collaborator of 2seventy bio, Inc.) of Regeneron’s MAGE-A4 cell therapy, which contains a Medigene generated T cell receptor (TCR) targeting MAGE-A4. “We are excited that this program is moving forward, incorporating our TCR directed at MAGE-A4 into the clinic and potentially providing the first clinical validation of our unique TCR discovery and generation capabilities and our End-to-End Platform technologies,” said Dr. Selwyn Ho, Chief Executive Officer of Medigene. “We look forward to the results of this trial and remain committed to delivering best-in-class, differentiated T cell receptors for use in multiple TCR-guided therapies for patients with solid tumors.” This payment has been included in the current financial guidance provided by the Company, and therefore confirmation of this milestone does not change 2024 guidance. --- end of press release --- About Medigene AGMedigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Its End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique and distinctive attributes that can be utilized in multiple therapeutic modalities, such as off-the-shelf TCR-guided T cell engager (TCR-TCE) therapies (MDG3010), TCR-natural killer cell (TCR-NK) therapies and T cell receptor engineered T cell (TCR-T) therapies (MDG1015). For more information, please visit https://medigene.com/ This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only. Medigene AGPamela KeckPhone: +49 89 2000 3333 01Email: investor@medigene.com In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

— Funds to accelerate the commercialization of Lentiviral Vectors and Adeno-Associated Viral Vectors SHENZHEN, China, March 7, 2024 /PRNewswire/ -- Shenzhen Eureka Biotechnology Co., Limited (EurekaBio), a leading upstream supplier in the cell and gene therapy field, announced the completion of its Series B+ financing, exceeding $40 million. The financing was led by YUEXIU INDUSTRIAL FUND, with participation from numerous well-known Chinese funds, as well as follow-on investments from U.S. funds. The funds will support the commercial implementation of large-scale production technology for Lentiviral Vectors (LVV), advance research and development around large-scale production technology for Adeno-Associated Viral Vectors (AAV), promote comprehensive solutions for cell therapy manufacturing, accelerate global market expansion efforts, and bolster the overall growth of the company. "Innovation in viral vector production technology is a crucial factor driving the cost reduction and efficiency improvement of commercializing cell and gene therapy drugs," said Marl Ma, CEO of EurekaBio. "With numerous pharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) actively seeking solutions for large-scale viral vector production, the future trajectory points towards stable cell lines as the key direction. In addition to successfully commercializing the EuLV™ Lentiviral Vector Production System, we will also develop stable cell lines for the production of other types of viral vectors, such as AAV – a strategic initiative that provides a broad range of much-needed products, technologies, and services." EurekaBio's core innovation lies in the EuLV™ Lentiviral Vector Production System, a cutting-edge technology that transforms the large-scale production of lentiviral vectors using stable cell lines and a serum-free suspension system. The company proudly stands as the world's pioneer in successfully bringing this groundbreaking technology to commercialization. In contrast to traditional transient transfection production methods, the EuLV™ Lentiviral Vector Production System eliminates the necessity for plasmids, resulting in cost savings related to plasmid production and streamlining the overall production process. This innovative system significantly improves the consistency of lentiviral vectors, offering better control over batch-to-batch variations. Moreover, the EuLV™ system adopts a high-density suspension culture, which substantially increases unit titer levels, reduces production batches and associated costs and meets the requirements of large-scale lentiviral vector production. The EuLV™ system presents a next-generation solution for lentiviral vector production to power cell and gene therapies, and is also well positioned for global adoption. "As a prominent player focused upstream of cell and gene therapies, EurekaBio has demonstrated substantial progress in pioneering developments for cell and gene therapies through its independently crafted technologies and product," said Rong Lu,President of YUEXIU INDUSTRIAL FUND. "The company's unique business framework and extensive practical expertise of inspire confidence in the myriad potentialities for the company's future growth. We look forward to collaborating with this visionary team to jointly propel the rapid advancement of innovative cell and gene therapy-based drugs." Additionally, EurekaBio has developed an automated solution tailored for the complete spectrum of cell therapy manufacturing processes involving cell isolation, magnetic bead cultivation, viral transduction, cell expansion, concentration, washing formulation and packaging. Through this comprehensive approach, EurekaBio can produce cell therapies in a high-quality, cost-effective manner. EurekaBio Through the synergies of cross-disciplinary collaboration and technological innovation, EurekaBio has consistently pushed the boundaries of therapy. EurekaBio has brought forth advanced cellular drug production solutions and the EuLV™ lentiviral vector platform. These breakthroughs, including high-titer stable lentiviral vector packaging and producer cell lines, are poised to play a pivotal role in the global commercialization of CGT drugs. Our ultimate aim is to bring tangible benefits to patients worldwide by ushering in a new era of advanced and accessible therapies. SOURCE EurekaBio

BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the Company appointed Mr. Xin Fu, who has extensive finance-related experience, as the Chief Financial Officer (CFO). He reports to the Co-founder, Chairwoman and CEO of InnoCare Pharma, Dr. Jasmine Cui. Mr. Fu is responsible for the Company’s growth strategy, financial management, investment & financing activities as well as investor relations management, aiming to contribute to the Company’s globalization and operational efficiency to achieve the Company’s 2.0 objectives. Mr. Fu has over 20 years of financial management experience, including 15 years in the healthcare industry. Before joining InnoCare, Mr. Fu served as the Chief Financial Officer at JW Therapeutics, where he played a critical role in the completion the of IPO in the Hong Kong Stock Exchange, company strategy planning, investment and financing activities, etc. Prior to JW Therapeutics, Mr. Fu held multiple leadership positions at Pfizer China, including Chief Financial Officer and Chief Compliance Officer. He led the financial team to support the steady growth of company’s performance, oversaw major projects such as business restructuring, acquisitions and joint ventures, developed long-term strategic plans, and established multiple comprehensive systems for budget control and tax management. “We are delighted to welcome Mr. Fu joining InnoCare,” said Dr. Cui. “He has rich experience in strategic planning, investment and financing, financial management, and has been deeply engaged in the healthcare industry for many years. I believe his extensive experience and excellent expertise in financial management will further contribute to the Company’s globalization.” "I am honored to join InnoCare and make my contribution to drive the fast-growing period of Company 2.0. InnoCare's strong innovation capabilities and robust pipelines have left a profound impression on me. I look forward to working with this world-class team to contribute more to the Company's healthcare endeavors," Mr. Fu stated. Mr. Fu graduated from Fudan University majoring in accounting and holds a qualification of U.S. Certified Management Accountant (CMA). About InnoCare InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States. View source version on businesswire.com: Contacts Media Chunhua Lu 86-10-66609879 chunhua.lu@innocarepharma.com Investor Relations 86-10-66609999 ir@innocarepharma.com Source: InnoCare Pharma View this news release online at: